Advisers to the US Centers for Disease Control and Prevention (CDC) will meet on Thursday to vote on whether to recommend the use of two COVID-19 vaccine boosters tailored against the omicron variant.
A recommendation in favor of the modified vaccines by Pfizer Inc and its German partner BioNTech SE, as well as Moderna Inc is expected to pave the way for a rollout next week.
The US Food and Drug Administration is yet to authorize the two modified boosters, for which applications were submitted last week.
The so-called bivalent vaccines include both the currently dominant BA.4 and BA.5 omicron subvariants and the original version of the virus.
While Pfizer's vaccine would be for people aged 12 and older, Moderna's would be for those 18 and older.
The Advisory Committee on Immunization Practices will also meet on Friday but the CDC did not explain in detail the agenda for the day.
Omicron’s mutations impaired vaccine effectiveness: US CDCAlmost 40 percent of people hospitalized in the US with the COVID-19 subvariant that circulated this spring were vaccinated and boosted, highlighting ... Coronavirus
Moderna set to seek FDA approval of booster against omicron variantsModerna Inc. said that the company plans to file data with US regulators very soon requesting clearance for a booster shot targeting the latest ... World News
Vaccine patch offers more robust protection against omicron, delta COVID-19 variantsA COVID-19 vaccine patch is more effective at fighting variants such as delta and omicron than a traditional needle shot, a new study has found.The ... Coronavirus
Omicron BA.5 makes up 82 percent of COVID-19 variants in USThe BA.5 subvariant of omicron was estimated to make up 81.9 percent of the circulating coronavirus variants in the United States for the week that ... Coronavirus